Development of Photoswitchable Estrogen Receptor Ligands

Keisuke Tsuchiya, 1,a,b*, Tomohiro Umeno, 1,c,b* Genichiro Tsuji, 1 Hidetomo Yokoo, 1,b,d Masakazu Tanaka, 1 Kiyoshi Fukuhara, 1 Yosuke Demizu, 1,b,d* and Takashi Misawa 1,b*

1Graduate School of Pharmacy, Showa University; 1–5–8 Hatanodai, Shinagawa-ku, Tokyo 142–0064, Japan;
2National Institute of Health Sciences; 3–25–26 Tonomachi, Kawasaki-ku, Kawasaki 210–9501, Japan;
3Graduate School of Biomedical Sciences, Nagasaki University; 1–14 Bunkyo-machi, Nagasaki 852–8521, Japan; and
4Graduate School of Medical Life Science, Yokohama City University; 2–10–1 Wakaba, Mihama-ku, Kanagawa 261–0014, Japan.

Received December 23, 2019; accepted January 15, 2020

Photopharmacology has attracted attention as an approach for the development of novel therapeutics because it allows regulation of the bioactivity of compounds based on their conformational change by photoirradiation. Previously, we have reported several types of selective estrogen receptor (ER) modulators based on diphenylmethane skeleton. To develop novel photopharmacological reagents, we designed and synthesized a set of ER ligands based on azobenzene skeleton, which can switch its conformation following UV irradiation. Our results showed that after UV irradiation, the Z-form of the synthesized compound 9 interacted with ERα, with a Kᵦ value of 2.5 µM, whereas the E-form of compound 9 did not bind ability to ERα at 10 µM.

Key words estrogen receptor; photopharmacology; diazo moiety; fluorescent polarization assay

Introduction

Estrogen receptor (ER), which is a superfamily of nuclear receptors, plays pivotal roles in physiological actions, such as cell growth and bone marrow homeostasis. 1,2 17β-Estradiol, an endogenous ligand for ERα, binds to the ligand binding domain of ERα and promotes its transactivation, resulting in target gene transcription. It has been reported that ERα is overexpressed in 70% of breast cancer cells and that it plays an important role in promoting tumor progression. 3 Therefore, ERα may be a promising target for breast cancer therapy, and the several ERα antagonists have been developed 4–6 (Fig. 1). Among these, tamoxifen and raloxifen are well known as selective ER modulators and broadly used for breast cancer therapy. 6

Although tamoxifen shows promising antitumor effects against breast cancer cells, it also acts as an agonist against the uterus ERα 7 and such poor organ selectivity become a problem in its clinical use. To overcome poor organ selectivity, innovative strategies have been urgently required for development of novel ligands. Recently, photopharmacology has garnered attention as a promising strategy to regulate the bioactivity of compounds under UV irradiation. To date, several photopharmacological agents containing diazo, spiropryran, and diarylethenes moieties have been reported 8–10 (Fig. 2). Especially, compounds that contain a diazo moiety undergo trans-to-cis isomerization under irradiation with light of an appropriate wavelength. 8 Owing to its photochemical properties, the azobenzene moiety has been broadly utilized to change the conformation of compounds and control their bioactivities. 11

With the aim of development of novel ER ligands, we hypothesized that photopharmacological ER ligands are a promising strategy to overcome the organ selectivity of ER ligands in the treatment of breast cancer. Recently, photoswitchable Farnesoid X receptor (FXR) ligands based on GW4064, a representative FXR agonist, have been reported. 12 The compounds have a diazo moiety instead of the unsaturated double bond of GW4064, and their FXR activity is regulated by UV irradiation in cells. These findings suggested that photoswitchable reagents are applicable for intracellular proteins. Previously, Hashimoto and colleagues reported that diphenylmethane (DPM) skeleton can be a bioisoster of steroid skeleton, and appropriate modifications of DPM skeleton can be applied to develop several nuclear receptor ligands, such as vitamin D receptor and ERs. 13,14 Among these ligands, PBP showed potent antagonistic activity against ERα, with IC₅₀ value of 4.9 nM. 13 Furthermore, its diphenylsilane derivative also exhibits transactivation activity against ERα, with IC₅₀ value of 29.7 nM, 15 indicating that substitution of heptane chain with other atoms is applicable in the development of ER ligands. Hence, we designed and synthesized a set of photoswitchable ER ligands containing a diazo moiety (Fig. 3). Moreover, we

* These authors contributed equally to this work.

† To whom correspondence should be addressed. e-mail: demizu@nihs.go.jp; misawa@nihs.go.jp

© 2020 The Pharmaceutical Society of Japan
evaluated their UV spectra to confirm their conformational change after UV irradiation, and we investigated the binding of the synthesized compounds to ER\textsubscript{\alpha}.

**Results**

**Chemistry** Initially, we prepared a set of azobenzene derivatives 1–10, via coupling and modification of aryl diazonium species with phenolic compounds (Chart 1). Azobenzene 1, 2, 5, 8 and 9 were synthesized according to a previously reported method.\textsuperscript{16–20} Next, the phenolic hydroxy group on 1 and 8 was alkylated to afford 2–6 and 9, and both hydroxy groups in 1 were acetylated (7). To synthesize tetrafluoroazobenzene 8 and 9, 2,6-difluoroaniline and (4-amino-3,5-difluorophenyl)methanol were converted to diazonium salt via treatment with NaNO\textsubscript{2} in conc. HCl. Next, the resultant diazonium salt was subjected to a coupling reaction with 3,5-difluorophenol in the presence of aqueous NaOH, thus yielding tetrafluoroazobenzene with or without a hydroxymethyl group; methylation of a phenolic hydroxy group of compound 8 provided 9 as a mixture of E- and Z-isomers, but isomerization of Z- to E-isomer occurred during column chromatography.

Next, we evaluated the conformational changes in compounds 1–10 by measuring the UV spectra and the E/Z ratio of the compounds were determined using HPLC analysis. The UV spectra of compounds 1–10 are shown in Fig. 4. Compound 1 did not exhibit any conformational change after UV irradiation at 254 or 365 nm, whereas compounds 2, 6, and 7 showed dramatic conformational changes from E- to Z-form after UV irradiation at 365 nm. These results showed that alkylation of the phenol group may exert an advantage to their conformational change. However, further investigation revealed that the Z-isomer of compounds 2–7 was rapidly reversed to the E-form at room temperature (25°C) even in the dark; therefore, the effects of these conformational changes on the binding affinity of the compounds to ER\textsubscript{\alpha} could not be investigated. It has been reported that o-fluorination of diphenyl diazo compounds can stabilize and prolong the E/Z-conformation via their steric effect.\textsuperscript{21} On the basis of this report, we employed tetra-fluorinated diphenyl diazo compounds at the o-position, and confirmed their conformational change after UV irradiation. Compound 8 did not show any conformational change after UV irradiation, whereas compounds 9 and 10, which had four fluorine atoms at the o-position showed conformational changes after UV irradiation (Table 1; E/Z ratio: 9, 13/87; 10, 11/89), and their half-life (t\textsubscript{1/2}) in the E-form was prolonged because of their steric effects (Table 1; E/Z ratio after 16h incubation at 37°C: 9, 28/72; 10, 32/68). These data revealed that the phenolic hydroxy group at the p-position took disadvantages on conformational control by UV irradiation, and the compounds 9, and 10 could be a candidate as photoswitchable ER\textsubscript{\alpha} ligands.

Finally, to investigate the effects of conformational changes on the binding affinity of the compounds to ER\textsubscript{\alpha}, the binding of compounds 9 and 10 to ER\textsubscript{\alpha} was examined. The binding affinity of 9 and 10 was evaluated using fluorescent polarization (FP) assay kit following the manufacturer’s instruc-
As shown in Fig. 5, Z-isomer of compound 9 showed moderate binding affinity to ERα, whereas its E-isomer had no binding affinity even at 10 µM. Moreover, the Z- and E-isomers of compounds 10 bound to ERα, but the binding affinity of compounds 10 was lower than that of 9. These results showed that the Z-isomer of compounds 9 and 10 exhibited the higher binding affinity to ERα than did the E-isomer of both compounds, and that introduction of a hydroxymethyl group at the p-position decreased the binding affinity of the compounds to ERα.

In conclusion, we designed and synthesized a set of photo-switchable ER ligands based on diphenyldiazo skeleton. Introduction of fluorine at the o-position prolonged their half-life ($t_{1/2}$) as a Z-form by its steric effects. Moreover, the binding affinity of compounds to ERα was investigated using FP assay, and the results revealed that the Z-isomer of compound 9 showed higher binding affinity to ERα than did the E-isomer. Although the binding affinity of compound 9 was moderate compared to that of known ER ligands, such as tamoxifen, the ER binding affinity was controlled by UV irradiation, suggesting that compound 9 can be a promising candidate of a photoswitchable ERα ligand. The detailed structure-activity relationship (SAR) analysis and ERα-transactivation activity of compound 9 in the cells are in progress.

### Experimental

**General** All chemicals were purchased from Sigma-Aldrich (U.S.A.), FUJIFILM Wako Pure Chemical Corporation (Japan), and Tokyo Chemical Industry (Japan) and were used without further purification. TLC analysis was conducted using Merck silica gel 60 F254 pre-coated plates and visualized using a 254 nm/365 nm UV lamp, and iodine stain. Column chromatography was performed using silica gel (spherical, neutral) purchased from Kanto Chemical. 1H- and 13C-NMR spectra were recorded on a JEOL ECZ600 spectrometer, and measurements were carried out in CDCl$_3$ with 0.03% tetramethylsilane or dimethyl sulfoxide (DMSO)-d$_6$. High-resolution mass spectra (HR-MS) were measured using
a Shimadzu IT-TOF MS equipped with an electrospray ionization source.

(4-((4-Ethoxyphenyl)diazenyl)phenyl)methanol (3) To a solution of 4-(4-hydroxyphenyl) azobenzyl alcohol (1, 57.1 mg, 0.250 mmol) in N,N-dimethylformamide (DMF) (0.5 mL) were added K₂CO₃ (69.1 mg, 0.500 mmol) and 1-iodopropane (26.8 µL, 0.275 mmol) at 0°C, and the mixture was gradually warmed to 70°C. After being stirred for 4 h, the reaction mixture was diluted with EtOAc/n-hexane (1:3), and washed successively with 1 M HCl and brine. The organic layer was dried over Na₂SO₄ and concentrated in vacuo to give a crude product, which was purified by flash column chromatography on silica gel (50% EtOAc in n-hexane) to give title compound 3 (44.1 mg, 69%) as an orange solid. mp 126–128°C; 1H-NMR (600 MHz, CDCl₃) δ: 1.45 (2H, t, J = 7.8 Hz), 2.03 (1H, brs, 1H), 4.10 (2H, q, J = 7.8 Hz, 2H), 7.46 (2H, d, J = 8.4 Hz), 7.83 (2H, d, J = 6.6 Hz), 7.90 (2H, d, J = 6.6 Hz). 13C-NMR (151 MHz, DMSO-δ₆) δ: 14.72, 63.81, 64.85, 114.66, 122.71, 124.72, 127.41, 143.08, 146.83, 152.20, 161.48. HR-MS (electrospray ionization (ESI)) [M-H]⁺ Calcd for C₁₆H₁₉N₂O₂, 271.1489. Found, 271.1483.

(4-((4-n-Propylphenyl)diazenyl)phenyl)methanol (4) To a solution of 4-(4-hydroxyphenyl)azobenzyl alcohol (1, 57.1 mg, 0.250 mmol) in DMF (0.5 mL) were added K₂CO₃ (69.1 mg, 0.500 mmol) and 1-iodopropane (26.8 µL, 0.276 mmol) at room temperature, and the mixture was warmed to 70°C. After being stirred for 4 h, the reaction mixture was diluted with EtOAc/n-hexane (1:3), and washed successively with 1 M HCl and brine. The organic layer was dried over Na₂SO₄ and concentrated in vacuo to give a crude product, which was purified by flash column chromatography on silica gel (50% EtOAc in n-hexane) to give title compound 4 (44.7 mg, 66%) as an orange solid. mp 130°C; 1H-NMR (600 MHz, CDCl₃) δ: 0.94 (3H, t, J = 6.6 Hz), 2.16 (1H, brs), 3.98 (2H, t, J = 6.6 Hz), 4.72 (2H, d, J = 8.4 Hz). 365 nm 3 min 11% 89% E-Isomer

Table 1. E/Z Ratio of Compounds 9 and 10

| Compound | E-Isomer | Z-Isomer |
|----------|----------|----------|
| (E)-9    | 89%      | 11%      |
| (Z)-9    | 365 nm 3 min | 13% 87% |
| (Z)-9    | 37°C 16 h | 28% 72%  |
| (E)-10   | 94%      | 6%       |
| (Z)-10   | 365 nm 3 min | 11% 89% |
| (Z)-10   | 37°C 16 h | 32% 68%  |

Fig. 5. Binding Affinity of Each E/Z-Isomer of Compounds 9 and 10 to ERα as Examined by FP Assay
and conc. HCl (100 µL) in water (750 µL) was added dropwise NaNO₂ (15.6 mg, 0.226 mmol) in 1 M NaOH aq was added dropwise to the reaction mixture, and the mixture was stirred at the same temperature for 1 h. After acidified with 1 M HCl, the solution was extracted with EtOAc, and the combined organic phase was dried over MgSO₄. Removal of the solvent afforded a crude product, which was purified by column chromatography on silica gel (40% EtOAc in n-hexane) to give 3,5-difluoro-4-(2,6-difluoro-4-hydroxyphenyl) azobenzyl alcohol (S-1, 15.8 mg, 26%). To a solution of S-1 (15.8 mg, 52.6 µmol) in water (450 µL) were added K₂CO₃ (14.5 mg, 0.105 mmol) and iodo- methane (4.26 µL, 600 MHz, CDCl₃) δ: 3.88–3.77 (3H, m), 4.75–4.66 (2H, m), 6.61–6.37 (2H, m), 7.06–6.88 (2H, m). 13C-NMR (151 MHz, CDCl₃): 55.97, 56.17, 63.62, 63.81, 98.36 (d, J₂₀ = 23.1 Hz), 109.70 (d, J = 13.0 Hz). HR-MS (ESI) [M+H]+ Calcd for C₁₄H₁₀F₄N₂O₂, 315.0751. Found, 315.0755.

**UV Irradiation** AS ONE Handy UV Lamp SLUV-4 254/365nm was used as UV light source and UV spectra were measured on Jasco V-730 Spectrophotometer. Ten milli molar compounds in DMSO were dissolved in EtOH (final concentration 1 mM). UV irradiation was evaluated 254 nm for 3 min, followed by 365 nm in the same solution. E/Z ratio of 1 mM compounds were measured on HPLC after preservations at room temperature and 37°C for 16 h.

**Fluorescence Polarization Assay** The relative binding affinities of tested compounds for ERα were determined by fluorescence polarization-based competition binding assay using commercially available kits (P2698, Life Technologies, Inc.) according to the manufacturer’s instruction. After 1h, fluorescence polarization signals (mP values) were measured using the plate reader (EnVision 2105, PerkinElmer, Inc.) with a 480 nm excitation/535 nm emission filter. The fraction of compounds bound to ERα was correlated to the mP value and plotted against values of competitor concentration.

**Acknowledgments** This work was supported in part by Grants from AMED under Grant Number 19mk0101120j0002 (to Y. D.) and 19mk0101166j0001 (to T. M.), the Japan Society for the Promotion of Science (KAKENHI, Grants 15K18905, 18K14880 to T. M., 19K16333 to G. T, 17K08385 to Y. D. 18H05502 to Y. D.), the Terumo Foundation for Life Sciences and Arts (to T. M. and Y. D.), the Takeda Science Foundation (to T. M., and Y. D.), the Naito Foundation (to Y. D.), the NOVARTIS Foundation (Japan) for the Promotion of Science (to Y. D.), and Grant for Basic Science Research Project from the Sumitomo Foundation (to Y. D.).

**Conflict of Interest** The authors declare no conflict of interest.

**References**

1. Manolagas C. S., O’Brien A. C., Almeida M., *Nat. Rev. Endocrinol.*, 9, 699–712 (2013).
2. Imai Y., Youn M. Y., Kondoh S., Nakamura T., Kouzmenko T., Matsumoto T., Takeda I., Takao K., Kato S., *Ann. N. Y. Acad. Sci.*, 1173 (Suppl. 1), E31–E39 (2009).
3. Holst F., Stahl P. R., Ruiz C., Hellwinkel O., Jehan Z., Wendland M., Lebau A., Terracciano L., Al-Kuraya K., Janicke F., Sauter G., Simon R., *Nat. Genet.*, 39, 655–660 (2007).
4. Jordan V. C., *Br. J. Pharmacol.*, 147 (SI), 269 (2006).
5. Greise T. A., Cho S., Finley D. R., Godfrey A. G., Jones C. D., Lugar C. W. 3rd, Martin M. J., Matsumoto K., Pennington L. D., Winter M. A., Adrian M. D., Cole H. W., Magee D. E., Phillips D. L., Rowley E. R., Short L. E., Glasebrook A. L., Bryant H. U., *J. Med. Chem.*, 40, 146–157 (1997).
6. Howell A., Cuzzick J., Baum M., Buzdar A., Dowsett M., Forbes J. F., Hootin-Boes G., Houghton J., Locker G. Y., Tobias J. S., Lancer, 365, 60–62 (2005).
7. Pinkerton J. C., Conner E. A., *Climacteric*, 22, 140–147 (2019).
8. Dhammika Bandara H. M., Burdette S. C., *Chem. Soc. Rev.*, 41, 1809 (2012).
9. Mikit J. Y., *Chem. Soc. Rev.*, 104, 2751 (2004).
10. Irie M., *Chem. Rev.*, 100, 1685–1716 (2000).
11. Jafari R. M., Lakusta J., Lundgren J. R., Derda R., *Bioconjug. Chem.*, 27, 509–514 (2016).
12. Morstein J., Trads J., Hinnah K., Willems S., Berber M. D., Trauner M., Drerup J., Trauner D., *Chem. Soc. Rev.*, 11, 429–434 (2020).
13. Kainuma M., Kasuga J., Hosoda S., Wakabayashi K., Tanatani A., Nagasawa K., Miyachi H., Makishima M., Hashimoto Y., *Bioorg. Med. Chem. Lett.*, 16, 3213–3218 (2006).
14. Maruyama K., Nakamura M., Tomishige S., Sugita K., Makishima M., Hashimoto Y., Ishikawa M., *Bioorg. Med. Chem. Lett.*, 23, 4031–4036 (2013).
15. Kaijita D., Nakamura M., Matsumoto Y., Makishima M., Hashimoto Y., *Bioorg. Med. Chem. Lett.*, 22, 2244–2252 (2014).
16. Liu Z. X., Feng Y., Yan Z. C., He Y. M., Liu C. Y., Fan Q. H., *Br. J. Pharmacol.*, 24, 3751–3757 (2012).
17. Haung H., Juan A., Katsonis N., Huskens J., *Tetrahedron*, 73, 4913–4917 (2017).
18. Junge M. D., McGrath V. D., *J. Am. Chem. Soc.*, 121, 4912–4913 (1999).
19. Kay K. Y., Han K. J., Yu Y. J., Park Y. D., *Tetrahedron Lett.*, 43, 5053–5056 (2002).
20. Cho Z., Klain R., *Nano Lett.*, 19, 7106–7111 (2019).
21. Bléger D., Schwarz J., Brouwer A. M., Hecht S., *J. Am. Chem. Soc.*, 134, 20597–20600 (2012).